Polyethylene Glycol
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Polyethylene Glycol
- Polyethylene glycol: From an Unrecorded Original Indication to Congenital Ichthyosiform Erythroderma
Polyethylene glycol: From an Unrecorded Original Indication to Congenital Ichthyosiform Erythroderma
One-Sentence Summary
The evidence pack does not record what Polyethylene glycol (DB09287) was originally licensed to treat, and no mechanism of action data is currently available. The TxGNN model predicts a possible link to Congenital Ichthyosiform Erythroderma, but this is supported by no clinical trials and no published literature — the prediction stands on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the evidence pack |
| Predicted New Indication | Congenital Ichthyosiform Erythroderma |
| TxGNN Prediction Score | 99.03% |
| Evidence Level | L5 (model prediction only) |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for this drug is not currently available, and no original indication is recorded in the evidence pack, so no data-based link can be drawn between an original use and the predicted new indication.
Based on general pharmacological background (not derived from the evidence pack itself), polyethylene glycol is widely used as an excipient in topical formulations, where it can contribute to skin barrier hydration. This offers a plausible, general rationale for why a model might associate it with an ichthyosis-type skin condition, but this is a property of the molecule’s physicochemical class rather than evidence specific to this predicted indication. It should not be treated as mechanistic support.
The TxGNN score of 99.03% (rank 7,943) reflects model confidence only. In the absence of any mechanistic, trial, or literature evidence, this score cannot be interpreted as clinical or biological validation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
No MHRA marketing authorisations are recorded for this product. Market status is listed as not marketed, with 0 active licences in the evidence pack.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate has no clinical trial or literature support, no confirmed mechanism of action, and no recorded original indication — evidence level is L5, the lowest tier. A blocking data gap (missing product warnings/contraindications) also prevents any preliminary safety assessment.
To proceed, the following is needed:
- Confirmed mechanism of action (DrugBank query)
- Product warnings and contraindications (regulatory label/SmPC)
- At least preclinical or mechanistic literature specific to congenital ichthyosiform erythroderma
- Clarification of original licensed indication(s), if any exist
- UK marketing authorisation status confirmation, if the drug is to be considered for repurposing in this market
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.